Hong Zheng
Research Assistant 3 MSCards
About
Research
Publications
2026
Similar androgen receptor expression in male and female AML
Prabhu K, Qian F, Sarkar D, Zheng H, Paulson R. Similar androgen receptor expression in male and female AML. Blood Advances 2026, 10: 4108. PMID: 41921074, PMCID: PMC13261862, DOI: 10.1182/bloodadvances.2026020008.Peer-Reviewed Original ResearchMolecular Flexibility and Electrostatic Interactions Drive the Nanoscale Structure of Coiled-Coil GM130 Protein Condensates
Mateos-Gil P, Feito A, Cava D, Tejedor A, Almendro-Vedia V, Coleman J, Zheng H, Simanjuntak M, Goder J, Rothman J, Espinosa J, Pincet F, López-Montero I. Molecular Flexibility and Electrostatic Interactions Drive the Nanoscale Structure of Coiled-Coil GM130 Protein Condensates. PRX Life 2026, 4: 023021. DOI: 10.1103/lp87-svtc.Peer-Reviewed Original ResearchAtomic force microscopyNanoscale structuresMolecular dynamics simulationsPhase separationSupramolecular scaffoldsMolecular flexibilitySeparation capacityElectrostatic interactionsConformational transitionCoiled-coil proteinsForce microscopyAFM measurementsDrivers of phase separationPhase separation capacityVesicle tetheringGM130Conformation polymorphismProtein condensatesDisordered regionsMolecular basisStructural basisLipid bilayerMoleculesMolecularTwo-DimensionalPharmacological blockade of rho kinase enhances venetoclax responses in translational models of acute myeloid leukemia.
Golla U, Bhalodia R, Annageldiyev C, Patel S, Bollu V, Tan S, Cabot M, Feith D, Loughran T, Levine R, Mineishi S, Zheng H, Minagawa K, Hengst J, Sholler G, Desai D, Dovat S, Fisher-Wellman K, Claxton D, Sharma A. Pharmacological blockade of rho kinase enhances venetoclax responses in translational models of acute myeloid leukemia. Haematologica 2026 PMID: 41924919, DOI: 10.3324/haematol.2025.289041.Peer-Reviewed Original ResearchAcute myeloid leukemiaAML cellsAnti-apoptotic proteinsElevated reactive oxygen speciesBcl-2 inhibitorsConcomitant targetingSynergistic antileukemic activityPrimary AML cellsPro-apoptotic mediatorsXenograft model in vivoMyeloid leukemiaMitochondrial depolarizationAntileukemic activityBcl-2Patient cells ex vivoReactive oxygen speciesModel of acute myeloid leukemiaRho/ROCK pathwayAggressive hematologic malignancyVenetoclax activityPreclinical AML modelsCell lines in vitroCells ex vivoNormal cellsSynergistic cytotoxicitySurvival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial
Foran J, Sun Z, Luger S, Claxton D, Lazarus H, Arber D, Rowe J, Paietta E, Racevskis J, Garrett-Bakelman F, Zhang Y, Altman J, Al-Kali A, Zheng H, Pratz K, Broun E, Powell B, O’Dwyer K, Godwin J, Ofran Y, Litzow M, Tallman M. Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial. Blood Neoplasia 2026, 3: 100194. PMID: 41890705, PMCID: PMC13014643, DOI: 10.1016/j.bneo.2026.100194.Peer-Reviewed Original ResearchAcute myeloid leukemiaMRD-negative remissionInduction mortalityOverall survivalIntensive therapyMyeloid leukemiaAssociated with 5-year OSSecond-generation purine nucleoside analogNewly diagnosed AMLProspective phase 3 studySecondary acute myeloid leukemiaStandard-intensity therapyMedian Follow-UpAssociated with OSPhase 3 studyMultiparameter flow cytometryPhase 3 trialLow-intensity therapyLong-term outcomesPurine nucleoside analogsNon-inferiority designMRD-positiveInferior OSMRD negativityComplete remission
2025
Androgen receptor signaling as a new target for intervention in acute myeloid leukemia
Qian F, Sarkar D, Arner B, Peduzzi V, Bai Y, Ruan B, Jia B, Zheng H, Paulson R, Prabhu K. Androgen receptor signaling as a new target for intervention in acute myeloid leukemia. Blood Advances 2025, 9: 6326-6339. PMID: 40991369, PMCID: PMC12744263, DOI: 10.1182/bloodadvances.2024012639.Peer-Reviewed Original ResearchConceptsLeukemia-initiating cellsAcute myeloid leukemiaAR expressionMyeloid leukemiaAR levelsMurine modelAcute myeloid leukemia miceNormal bone marrow cellsPatient-derived AML cellsFood and Drug Administration-approved drugsLigand levelsAndrogen receptor signalingAcute myeloid leukemia cellsBone marrow cellsUnited States Food and Drug Administration-approved drugsAntiandrogen therapyAML treatmentProstate cancerAR signalingMarrow cellsAML cellsFemale recipientsReceptor 7Sex hormonesMouse modelEngineered suppressor T cells overexpressing IFN-α and PD-L1 inhibit GVHD but retain GVL effects in mice
Tian Y, Jia B, Lee C, Huang Q, Zhao C, Abraham C, Mo W, Zhang Y, Chen M, Wang Y, Blazar B, Zheng H, Zhang Y. Engineered suppressor T cells overexpressing IFN-α and PD-L1 inhibit GVHD but retain GVL effects in mice. Molecular Therapy 2025, 34: 898-915. PMID: 41234014, PMCID: PMC12882687, DOI: 10.1016/j.ymthe.2025.11.019.Peer-Reviewed Original ResearchConceptsGraft-versus-host diseasePD-L1Allo-HCTT cellsIFN-aImmunocompetent miceGraft-versus-host disease controlXenogeneic graft-versus-host diseaseEfficacy of allo-HCTEngineered human T cellsExpression of PD-L1Allogeneic hematopoietic cell transplantationLive cell therapyImmune regulatory cellsHematopoietic cell transplantationSuppressor T cellsLife-threatening complicationsImmune modulatory functionsHuman T cellsPD-1+GVL effectStable expressionRegulatory cellsEffector differentiationCell transplantationSafety and feasibility of intermediate-dose post-transplant cyclophosphamide for graft-versus-host disease prophylaxis
Venugopal N, McGowan A, Inoue Y, Zheng H, Cioccio J, Rakszawski K, Songdej N, Nickolich M, Naik S, Ehmann C, Sivik J, Mierski J, Silar B, Vajdic C, Shike H, Mineishi S, Minagawa K. Safety and feasibility of intermediate-dose post-transplant cyclophosphamide for graft-versus-host disease prophylaxis. Annals Of Hematology 2025, 104: 6451-6462. PMID: 41081866, PMCID: PMC12764680, DOI: 10.1007/s00277-025-06657-8.Peer-Reviewed Original ResearchGraft-versus-host diseasePost-transplant cyclophosphamideGraft-versus-host disease prophylaxisHematopoietic stem-cell transplantationDonor chimerismHistorical cohortSevere chronic graft-versus-host diseaseAcute graft-versus-host diseaseAllogeneic hematopoietic stem-cell transplantationChronic graft-versus-host diseaseOptimal doseMedian time to neutrophilIntermediate-dose groupStandard-dose groupComplete donor chimerismTime to neutrophilStem-cell transplantationPoor performance statusLymphocyte engraftmentPlatelet engraftmentNeutrophil engraftmentAcceptable toxicityAlveolar hemorrhageConsecutive patientsPerformance statusPrior status of graft‐versus‐host disease affects donor lymphocyte infusion outcomes in patients with relapsed haematological malignancies after allogeneic stem cell transplantation
Velasco C, Inoue Y, Cioccio J, Rakszawski K, Songdej N, Nickolich M, Zheng H, Naik S, Ehmann C, Mierski J, Silar B, Vajdic C, Greiner R, Brown V, Mineishi S, Shike H, Minagawa K. Prior status of graft‐versus‐host disease affects donor lymphocyte infusion outcomes in patients with relapsed haematological malignancies after allogeneic stem cell transplantation. British Journal Of Haematology 2025, 207: 515-524. PMID: 40534233, PMCID: PMC12378914, DOI: 10.1111/bjh.20215.Peer-Reviewed Original ResearchConceptsGraft-versus-host diseaseHistory of graft-versus-host diseaseDonor lymphocyte infusionAllogeneic stem cell transplantationStem cell transplantationOverall survivalCell transplantationDeveloped graft-versus-host diseaseEffect of donor lymphocyte infusionsGraft-versus-leukemia effectRelapsed haematological malignanciesLymphocyte infusionDonor chimerismHaematological malignanciesNo significant differencePatientsSignificant differenceAlloHSCTRelapseTransplantationDiseaseFDCMalignancyChimerismInfusionCytotoxic lymphocytes induced by engineered human dendritic cells mediate potent anti-leukemia activity
Zhao C, Jia B, Jiang Y, Shike H, Annageldiyev C, Cioccio J, Minagawa K, Mineishi S, Ehmann W, Schell T, Cheng H, Zheng H. Cytotoxic lymphocytes induced by engineered human dendritic cells mediate potent anti-leukemia activity. Cancer Immunology, Immunotherapy 2025, 74: 117. PMID: 39998689, PMCID: PMC11861774, DOI: 10.1007/s00262-025-03971-y.Peer-Reviewed Original ResearchConceptsCytotoxic T cellsLeukemia-associated antigensAcute myeloid leukemiaAcute myeloid leukemia treatmentT cellsAdoptive transferDendritic cellsAdoptive transfer of cytotoxic T-cellsClinically relevant PDX modelGeneration of cytotoxic T cellsPatient-derived T cellsAdoptive T-cell transferEffective treatment of acute myeloid leukemiaEffective treatmentTreatment of acute myeloid leukemiaMonocyte-derived dendritic cellsPatient-derived AML cellsT-cell transferHuman telomerase reverse transcriptaseBlasts in vitroNaive T cellsHuman dendritic cellsTelomerase reverse transcriptaseAnti-leukemia activityGrowth in vivo
2024
Sensitivity and Specificity of Chimerism Tests in Predicting Leukemia Relapse Using Increasing Mixed Chimerism
Zhang R, Shang Y, Cioccio J, Rakszawski K, Nickolich M, Ehmann C, Inoue Y, Naik S, Rybka W, Zheng H, Mierski J, Silar B, Liao J, Greiner R, Brown V, Claxton D, Ning J, Zhou S, Mineishi S, Minagawa K, Shike H. Sensitivity and Specificity of Chimerism Tests in Predicting Leukemia Relapse Using Increasing Mixed Chimerism. Journal Of Molecular Diagnostics 2024, 26: 1159-1170. PMID: 39603755, DOI: 10.1016/j.jmoldx.2024.09.003.Peer-Reviewed Original ResearchConceptsT cellsChimerism testingLeukemia relapseMixed chimerismCumulative incidenceShort tandem repeat methodCumulative incidence of relapseT-cell chimerismIncidence of relapseStem cell transplantationT-cell contaminationT cell removalAcute lymphocytic leukemiaAcute myeloid leukemiaCombination of quantitative PCRRelapsed patientsMyelodysplastic syndromeChimerism levelsCell chimerismCell transplantationLymphocytic leukemiaMyeloid leukemiaDisease activityFalse-positive rateRelapse
Get In Touch
Contacts
Email